Esmya rejection hits Allergan's streamlining
A US FDA complete response letter has dealt Allergan’s hopes of finding a buyer for its women’s health unit a serious blow.
First-quarter floats see haves pulling away from the have-nots
Demand for new issues remains sluggish - only eight private biotechs managed to pull off an IPO in the first quarter of 2017.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.